During progression from single cancer cells to a tumor mass and metastases, tumor cells send signals which can subvert their tissue microenvironment. These signals involve soluble molecules and various extracellular vesicles, including a particular type termed exosomes.
Introduction
Cell-autonomous acquisition of new properties such as proliferation and resistance to programmed death is not sufficient for a cell to become a tumor (1) Various types of membrane vesicles are released by cells, and a subpopulation called exosomes has began receiving extensive attention in the past 4 years (7). Exosomes are small vesicles (50-100 nm in diameter) formed intracellularly in endocytic multivesicular compartments, and are released upon fusion of these compartments with the plasma membrane. Other vesicles, more heterogeneous in size (50 to 1000 nm), can be released from the cell surface, by a budding process similar to that used by some viruses. Exosomes are secreted by most cell types, including tumor and immune cells. Contradictory functions of tumor exosomes have been reported in vitro. On one hand, exosomes contain and transfer tumor antigens to dendritic cells for presentation of these antigens to T lymphocytes (8, 9) , but on the other hand, they display inhibitory effects on effector immune responses (10, 11) , and they have recently been proposed to promote metastasis (12) We have recently shown that the small GTPases RAB27A and RAB27B are critically required for exosome secretion by HeLa cells (13) . RAB27A/B are known to control intracellular trafficking and regulated secretion of lysosome-related organelles (14, 15) . In HeLa cells, we showed that spontaneous secretion of exosomes from CD63-containing compartments was strongly decreased if expression of either RAB27A or RAB27B was knocked-down by shRNA, whereas secretion of a soluble protein through the constitutive secretion pathway was not affected. We thus knocked-down Rab27a/b in mouse tumor cells to address the physiological functions of exosome secretion in vivo.
Our results show that, in two mammary carcinoma cells, 4T1 and TS/A, Rab27a is required for exosome secretion, whereas Rab27b is not. In vivo, growth and metastasis of 4T1 is impaired by Rab27a inhibition, which prevents systemic mobilization of a pro-tumoral population of neutrophils, whereas for TS/A, neither local growth nor formation of metastasis (which is very limited for this cell line) are affected. Rab27a is also involved in the secretion of some non exosome-associated proteins by the two cell lines, especially the pro-metastatic matrix metalloprotease (MMP) 9. Finally, we show complementary effects of exosomes, soluble cytokines and/or metalloproteases in modulation of the immune system by the growing tumors: a different quantitative and qualitative secretion of both exosomes and soluble proteins by 4T1 and TS/A explains their different dependency to Rab27a. In conclusion, our results highlight a pro-tumoral function of Rab27a expression, mediated by both exosome-dependent and -independent secretions, in some, but not all, tumors. Rab27b expression, cells infected with shRNA-expressing lentiviruses were selected and maintained in medium containing 5 μg/mL puromycin (Invitrogen). Cells were used within one month after lentivirus infection. Independent experiments were performed with batches of independently infected cells.
Materials and Methods

Mice
Reagents
Detailed list of antibodies for FACS and Western Blotting is given as supplemental materials.
Mouse Anti-Rab27a was generated in our lab (M. Seabra (14)). pLKO.1puro plasmids allowing expression of shRNA specific for mouse Rab27a or Rab27b, or a scrambled sequence of shRNA to GFP as control (Scr), and a puromycin resistance gene were obtained by L.F.Moita from the library described in (16) .
Exosome purification and characterization
Exosome purification was performed as previously described by differential ultracentrifugation (17) , from 48 hours-conditioned medium (CM) generated in complete medium depleted from calf serum-derived exosomes. 
In vivo tumor growth and metastasis development
Mice were injected subcutaneously in the mammary fat pad region with 50,000 cells, or intravenously with 100,000 cells. Tumor volume (= length x width x [(length + width)/2]) was measured twice weekly. Mice were sacrificed when tumors reached 1,500 mm 3 , or 20 days after intravenous injection. Lungs were fixed in AFA and nodules were manually counted.
Anti-Ly6G antibodies were injected everyday i.p. at 50 (d3) and 25 μg/mouse (d4-d15), and twice a day at 50 μg/mouse (d16-d18). Scr-4T1 or Scr-TS/A exosomes were injected into tumors in 50 μl of PBS at 1, 2, and 5 μg/tumor (day 3, 6, and 9 onwards respectively).
Analysis of immune cells by flow cytometry
Single cell suspensions from organs or from bone marrow cultures stained with mixed fluorescent antibodies were acquired on a MacsQuant (Miltenyi Biotech). Analyses were performed with FlowJo software.
Analysis of secreted factors
Soluble secreted factors were analyzed in CM before exosome purification. CM depleted or not of exosomes (by 1h ultracentrifugation at 100,000 g), cell lysates and exosomes (in 0.5% 
Results
Differential expression of Rab27a and Rab27b in mouse tumor cells and efficient inhibition by shRNA
We first analyzed the expression of Rab27a and Rab27b in six mouse tumor cells of different tissue origins. Rab27a mRNA was strongly expressed in the melanoma B16F10, whereas Rab27b was undetectable ( Figure 1A ). By contrast, Rab27b was readily detected in a bladder carcinoma, MB49, where Rab27a expression was weak. The fibrosarcoma MCA101 expressed both Rab27a and Rab27b at low levels, and two mammary carcinomas, TS/A and 4T1, expressed both genes at equivalent and readily detectable levels. Analysis of Rab27a expression at the protein level confirmed the mRNA results ( Figure 1B ).
As previously done in the HeLa cell line, which expresses both genes at equivalent levels ((13)), we used lentiviruses expressing shRNA to mouse Rab27a or Rab27b, or a control nonmurine gene (Scr), to infect the two mammary carcinoma cell lines. Among five shRNA sequences specific for Rab27a (respectively Rab27b), only sh27a2 (respectively sh27b1) induced significant downregulation of Rab27a without major alteration of expression of Rab27b (respectively Rab27a), in both TS/A and 4T1 (supplemental Figure S1 , Figure 1C ).
Western blot analysis confirmed a strong decrease of Rab27a protein in the sh27a2-expressing cells, with no significant modification in the sh27b1-expressing ones ( Figure 1D ).
Inhibition of Rab27a, but not Rab27b, affects exosome secretion
Exosomes were purified by differential ultracentrifugation from conditioned culture medium Therefore, the 4T1 tumor has developed a Rab27a-dependent capacity to modulate the host's immune system, namely neutrophils, to its own advantage, whereas TS/A does not rely on such immune system-dependent mechanism to grow.
Inhibition of Rab27a affects secretion of some non exosome-associated proteins
We then asked whether secretion of non-exosome associated molecules could be also affected upon Rab27a inhibition. Secretion of 144 soluble or membrane-associated proteins was measured by antibody microarrays in CM of cultured cells (supplemental Figure S4 ). Twentythree proteins were secreted above the background level, with differences in the secretomes of 4T1 and TS/A, especially extracellular proteases (pro-MMP9, MMP2 and MMP3), and cytokines and chemokines modulating myeloid cells and neutrophils (G-CSF/Csf3, MCP-1/Ccl2, RANTES/Ccl5) (21, 22) . Interestingly, Rab27a inhibition seemed to change the level of secretion of a subset of these proteins.
We thus used quantitative assays to measure secretion of the most relevant proteins by 4T1
and TS/A upon inhibition of Rab27a. We confirmed that 4T1 secretes high levels of pro-MMP9 and MMP3, whereas TS/A secretes high level of MMP2 and some pro-MMP9.
Rab27a inhibition abolished secretion of pro-MMP9 in both cells, without affecting secretion of either MMP3 or MMP2 ( Figure 5A ). Since secretion of some MMPs in association with membrane vesicles including exosomes has been described (23, 24) , reduced secretion of MMP9 in Rab27a-impaired cells could be due to reduced exosome secretion. However, by cells, we showed that the vast majority of MMP9 is secreted by 4T1 ( Figure 5B ) and TS/A (not shown) as a soluble form, rather than associated with exosomes. As a control, we confirmed that the vesicle-associated protein Mfge8 (25) was detected in these conditions at comparable levels in exosomes (Exo) and the CM (Figure 5B ), where its amount was decreased by at least 30% after exosome depletion. Thus Rab27a inhibition independently impairs exosome and MMP9 secretion.
The effects of Rab27a inhibition on cytokine and chemokine secretions were also contrasted.
4T1 secretes at higher level than TS/A the neutrophil-specific growth factor G-CSF, and at lower levels the myeloid cell chemotactic factors MCP-1 and RANTES ( Figure 5C ). Upon 
To determine whether exosomes could be responsible for the diverse patterns of immune cells We had previously shown in HeLa cells that RAB27A and RAB27B were required for efficient secretion of exosomes but not of a protein secreted through the regular secretion pathway (13) . Here, in two murine tumor models, Rab27a is required for secretion of exosomes, but also of non exosome-associated MMP9, whereas it inhibits secretion of a subset of cytokines. Similar observations have recently been published on the B16F10 melanoma cell line, where Rab27a shRNA decreased secretion of exosomes and also of some angiogenic growth factors (PlGF, PDGF), while increasing secretion of protease inhibitors (TIMP1) (12) . Complex roles of Rab27a in regulated secretion have been described in various secretory cells (26) (27) (28) (29) . Further studies will be required to determine the molecular mechanisms responsible for Rab27a-regulated expression and/or secretion by tumor cells of some cytokines and we are currently performing such analyses for proteases (C. Recchi, M. Seabra et al, in preparation). In any case, our observations show that Rab27a inhibition does not affect exlusively exosome secretion, and thus its use to understand the functions of exosomes in vivo must be completed, as we did here, with experiments to distinguish the relative contribution of cytokines and vesicles in the phenotypes observed. Furthermore, we observed that Rab27b inhibition did not affect the secretion of exosomes by the two murine carcinomas as it did in HeLa cells (13) . Thus Rab27 proteins are not universal regulators of exosome secretion, and our results highlight the diversity of intracellular compartments and of the molecular machineries used by different cell types for trafficking and fusion of these compartments. The second important observation reported here is that Rab27a inhibition modulates differently in vivo growth of two tumor cell lines of the same tissue origin. 4T1 (30) and TS/A (31) are two mammary adenocarcinomas, but the latter has been described as more immunogenic than the former (32), and in our hands it was less metastatic. We chose these cells to study the physiological functions of in vivo secreted exosomes, because both had been shown to secrete in vitro exosomes with immunosuppressive potential (19, 20) : inhibiting NK cell activity in vivo, inducing accumulation in spleen of CD11b+/Gr1+ cells (the anti-Gr1 antibody labels Ly6C and Ly6G), preventing proper differenciation of dendritic cells induced by GM-CSF in vitro (19) , and promoting expression of myeloid suppressor cell genes (33, 34) . Another group also showed that exosomes from various mouse tumor cell lines, including TS/A, promoted the differenciation in vitro of CD11b+/Gr1+ cells with suppressor effects on adaptive immune responses (35) . In our work, by inhibiting Rab27a gene expression, we decreased secretion of exosomes by more than 50% in the two cell lines, but this led to decreased tumor growth in vivo of only one of them. Based on our in vivo and in vitro data, we propose that soluble cytokines and exosomes secreted in vivo by 4T1 enter the blood circulation and reach the bone marrow (as shown before for injected exosomes (19) ). There, cytokines promote proliferation of granulocyte precursors, whereas exosomes orient their differenciation into neutrophils. These cells will then leave the bone marrow to reach lymphoid organs and eventually the tumor. In this context, TS/A does not secrete the cytokines necessary to promote granulocyte differenciation, and its exosomes are either not efficient at orienting granulocyte differenciation or not able to leave the tumor to reach myeloid precursors. Identifying the exosomal components responsible for the observed functional difference in TS/A and 4T1 will be the subject of future work.
The way immune cells mobilized by 4T1 participate in tumor progression is also not fully (38), thus the pro-metastatic effect of Rab27a in 4T1 is probably due to its role in MMP9 secretion. TS/A, by contrast, secretes another gelatinase, MMP2, whose secretion is not affected by Rab27a inhibition, and whose role in degrading extracellular matrix and promoting invasion has been previously shown in human breast cancer cell lines (39). Our observation that two different mouse mammary carcinoma secrete completely different patterns of metalloproteases with different dependence on Rab27a thus suggests that the effect of Rab27a on tumor cell's ability to degrade the extracellular matrix, like the effect on the immune system, will vary from one cell to another.
In conclusion, our work conclusively demonstrates that local secretion of exosomes by a tumor in vivo can promote tumor progression, but also that it would be very dangerous to generalize such a mechanism to all tumors, and to propose that "tumor-derived exosomes promote tumor progression" whatever the tumor and the model studied. Keeping in mind the idiosyncrasy of each tumor is very important for researchers, but also for clinicians, and this idea is at the basis of the currently expanding trend of "personalized therapies" taking into account for treatment the specific characteristics of each individual and his/her tumor. 
